Avara agrees to acquire AstraZeneca facility
"We are excited to have the Avlon organization join the Avara team and to add this significant capability to the Avara company," Avara Chairman and CEO Tim Tyson said. "We are honored to have the strategic partnership with AstraZeneca and to manufacture key products for them. We are excited to be able to transition this AstraZeneca center of technical excellence to a worldwide pharmaceutical services center of excellence. This exceptional facility will be the fifth site in our global network with other facilities in the US, Puerto Rico, Ireland and now the UK.”
According to the agreement, 210 Avlon employees who are currently working at the site will remain employed there. The plant will also continue to manufacture pharmaceutical products under the AstraZeneca name on a contractual basis. AstraZeneca will be able to continue to manufacture high-quality products at the facility.
"We thank the AstraZeneca employees in Avlon for their dedication, and we wish them well as they transition to Avara," AstraZeneca EVP Supply, EMEA, Marc Jones said.